Evotec SE (NASDAQ: EVO) announced the appointment of Dr. Ingrid Müller as Chief Operating Officer, effective May 1, 2026. Müller will join the company's Management Board and oversee global operations and implementation of the Horizon initiative.

Müller brings more than 20 years of international leadership experience in the life sciences industry across operations, strategy, supply, procurement and research and development integration. In her new role, she will focus on quality, productivity, scalability, delivery, cost management and technological improvements across the business.

Most recently, Müller served as Vice President Portfolio Strategy & Execution at CureVac. She previously held senior international leadership positions at Sanofi and Fresenius Kabi, where she worked on supply resilience, make-or-buy strategies, growth and margin expansion, and delivered annual savings and cash-flow improvements.

"Ingrid has built a broad international leadership profile defined by strategic perspective, operational discipline and the ability to lead cross-functional execution and transformation," said Dr. Christian Wojczewski, Chief Executive Officer of Evotec.

Evotec operates as a life science company focused on drug discovery and development, working with pharmaceutical companies, biotechnology firms, and academic institutions. The company employs more than 4,800 people across sites in Europe and the United States.